Search Results

Intrommune Therapeutics, Inc., a biotechnology company committed to developing a patient-friendly treatment platform for people with peanut and other food allergies, announces data in a late-breaking poster presentation at this year’s American Academy of Allergy, Asthma and Immunology Annual Scientific Meeting in Washington, D.C. supporting Oral Mucosal Immunotherapy as a potential new form of food allergy treatment.

Approved earlier this month for children and adults with one or more food allergies, Xolair in a Phase III study reduced severe allergic reactions in patients suffering from multiple food allergies.

Genentech, a member of the Roche Group, announced that the U.S. Food and Drug Administration has approved Xolair® for the reduction of allergic reactions, including anaphylaxis, that may occur with accidental exposure to one or more foods in adult and pediatric patients aged 1 year and older with IgE-mediated food allergy.

Novartis announced that the US Food and Drug Administration has approved Xolair® for the reduction of allergic reactions, including anaphylaxis, that may occur with accidental exposure to one or more foods in adult and pediatric patients aged 1 year and older with IgE-mediated food allergy.

bioMérieux, a world leader in in vitro diagnostics for 60 years, has entered into a strategic research collaboration with the US Food and Drug Administration, Center for Food Safety and Applied Nutrition, Offices of Applied Research and Safety Assessment and Regulatory Science to develop tools to combat food-borne pathogens.